 The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc NASDAQ: SAVA manipulated data key to its case for its experimental Alzheimers drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that certain government agencies had asked the Company for documentation. 